Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Listed
Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 790 across all filing types
Latest filing 2025-05-13 Interim / Quarterly Rep…
Country SE Sweden
Listing ST MOB · 6 venues

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Moberg Pharma AB for the period January–March 2025. It contains comprehensive financial data, including income statements (Nettointäkter, EBITDA, EBIT, result per share), business updates, management commentary, and operational highlights. It is not a mere announcement of a report, but the report itself, containing substantive financial analysis and performance metrics for the first quarter. Q1 2025
2025-05-13 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – March 2025' and contains detailed financial data including net revenue, EBITDA, operating profit, and earnings per share for the first quarter. It also includes management commentary, significant events, and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-13 English
Kallelse till årsstämma i Moberg Pharma AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kallelse till årsstämma i Moberg Pharma AB (publ)" which translates to 'Notice of Annual General Meeting in Moberg Pharma AB (publ)'. The text details the date, time, location, procedures for shareholder participation, voting rights, and presents a detailed agenda (Dagordning) for the meeting, including proposals for board elections, auditor appointments, remuneration, and guidelines for compensation and the nomination committee. These elements are characteristic of a formal notice for an Annual General Meeting (AGM). While it contains elements related to remuneration (DEF 14A) and governance (CGR), the primary purpose and structure of the document is the official summons and agenda for the AGM. Therefore, the most appropriate classification is AGM-R.
2025-04-22 Swedish
Notice of Annual General Meeting in Moberg Pharma AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Annual General Meeting in Moberg Pharma AB (publ)" and details the date, location, procedures for attendance, proposed agenda items (including election of directors, approval of reports, remuneration, and incentive programs), and specific proposals related to the meeting's resolutions. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2025-04-22 English
Annual Report (ESEF) 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-04-11 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Innehavare') for Moberg Pharma AB (publ), specifically reporting a 'Köp' (Buy) transaction by an entity named How100.ai, resulting in a new total holding of 5.50002% of shares. This structure, focusing on insider/significant shareholder transactions and reporting changes in ownership percentage, directly corresponds to the definition of Director's Dealing or Major Shareholding Notification. Since the transaction is reported by an external entity (How100.ai) crossing a 5% threshold, it is most accurately classified as a Major Shareholding Notification (MRQ) or potentially Director's Dealing (DIRS) if the holder is an executive/director. Given the explicit reporting of crossing a 5% threshold ('Gränsvärde för antal aktier 5 %') and the detailed breakdown of share counts before and after the transaction, MRQ is the most precise fit, although DIRS is also plausible if the holder is an insider. However, the structure strongly resembles mandatory notifications of significant ownership changes. I will select MRQ as the primary classification for significant ownership changes.
2025-03-04 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.